Literature DB >> 9426397

Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.

R Wellenreuther1, A Waha, Y Vogel, D Lenartz, J Schramm, O D Wiestler, A von Deimling.   

Abstract

Meningiomas frequently show mutational inactivation of the neurofibromatosis type 2 tumor suppressor gene (NF2 gene). In a previous study, mutations were preferentially observed in the fibroblastic and transitional subtypes (75%), whereas the meningothelial variant was significantly less affected (25%). To study a potential role of the NF2 gene on the transcriptional level, we have analyzed NF2 transcripts in 67 meningiomas of different subtypes. A competitive reverse transcriptase-PCR assay with an external NF2 gene standard was used for quantitative mRNA analysis. Fibroblastic and transitional meningiomas exhibited significantly lower levels of NF2 mRNA compared with meningothelial variants (p = 0.001, unpaired t test). These data support the concept of a distinct molecular pathway in the formation of meningothelial meningiomas independent from the NF2 gene or its gene product merlin/schwannomin. In addition, in these tumors, NF2 expression was reduced by a factor of 10 (p < 0.001, unpaired t test) in those meningiomas with NF2 gene mutations suggesting decreased stability or impaired transcription of mutated NF2 mRNA. In conclusion, our data provide further evidence for molecular differences between subtypes of meningiomas and support an NF2-independent pathogenesis of meningothelial meningiomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426397

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

Review 1.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

2.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 3.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

4.  Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma.

Authors:  M E Baser; T Y Poussaint
Journal:  J Med Genet       Date:  2005-06-24       Impact factor: 6.318

Review 5.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

6.  Mesothelin expression in the leptomeninges and meningiomas.

Authors:  Mahlon D Johnson; Fran Vito; Mary J O'Connell
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

7.  Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas.

Authors:  Yi-Hsuan Chen; Dueng-Yuan Hueng; Wen-Chiuan Tsai
Journal:  Int J Mol Sci       Date:  2018-10-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.